Showing results (31-40 of 90) with videos related to
Sort By:
Pageof 9
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 20, 2025
After a CDK4/6 Inhibitor: State of the Art in Hormone Receptor-Positive Metastatic Breast CancerJimmitti Teysir, Maxwell R Lloyd, Samer Alkassis, et al.International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics|June 25, 2025
Diffuse peritoneal inclusion cysts masquerading as disseminated gynecologic malignancy in post-menopausal females: Two cases and a review of the literatureHadley W Reid, Seth A Wander, Carlos Parra-Herran, et al.Breast Cancer Research : BCR|August 14, 2025
Comparative efficacy of first- versus second-line CDK4/6 inhibition in hormone receptor-positive, HER2-negative metastatic breast cancerLis Victoria Ravani, Zahra Bagheri, Adam M Brufsky, et al.Proceedings of the National Academy of Sciences of the United States of America|May 28, 2009
RSK1 drives p27Kip1 phosphorylation at T198 to promote RhoA inhibition and increase cell motilityMichelle D Larrea, Feng Hong, Seth A Wander, et al.Breast Cancer Research and Treatment|July 30, 2010
Combined Src and ER blockade impairs human breast cancer proliferation in vitro and in vivoYi Chen, Edwin A Alvarez, Diana Azzam, et al.Journal of Medicinal Chemistry|October 16, 2020
Doxorubicin and Aclarubicin: Shuffling Anthracycline Glycans for Improved Anticancer AgentsDennis P A Wander, Sabina Y van der Zanden, Gijsbert A van der Marel, et al.The Journal of Physical Chemistry. B|April 21, 2006
Aluminum chloride as a solid is not a strong Lewis acidJ Krishna Murthy, Udo Gross, Stephan Rüdiger, et al.Journal of Medicinal Chemistry|August 1, 2024
Novel <i>N,N</i>-Dimethyl-idarubicin Analogues Are Effective Cytotoxic Agents for ABCB1-Overexpressing, Doxorubicin-Resistant CellsMerle A van Gelder, Yufeng Li, Dennis P A Wander, et al.JCO Oncology Practice|December 17, 2024
Efficacy of Subsequent Treatments After Disease Progression on CDK4/6 Inhibitors in Patients With Hormone Receptor-Positive Advanced Breast CancerLis Victoria Ravani, Pedro Calomeni, Maysa Vilbert, et al.Proceedings of the National Academy of Sciences of the United States of America|March 17, 2019
p27 transcriptionally coregulates cJun to drive programs of tumor progressionHyunho Yoon, Minsoon Kim, Kibeom Jang, et al.Pageof 9